- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | OKYO Pharma launches underwritten public offering of ordinary shares | 1 | Seeking Alpha | ||
| Do | OKYO Pharma Announces Public Offering of Ordinary Shares | 223 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| OKYO PHARMA Aktie jetzt für 0€ handeln | |||||
| Mi | OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners | 462 | GlobeNewswire (Europe) | LONDON and NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| Di | OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer | 229 | GlobeNewswire (Europe) | Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate, a blockbuster orphan therapy in corneal diseaseDr. Mantelli... ► Artikel lesen | |
| Di | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 30.01. | OKYO Pharma präsentiert Studienergebnisse zu Urcosimod auf jährlicher ASCRS-Tagung | 1 | Investing.com Deutsch | ||
| 30.01. | OKYO Pharma to present urcosimod NCP study results at ASCRS meeting | 1 | Investing.com | ||
| 30.01. | OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting | 306 | GlobeNewswire (Europe) | LONDON and NEW YORK, Jan. 30, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic... ► Artikel lesen | |
| 30.01. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 29.01. | H.C. Wainwright reiterates Buy rating on OKYO Pharma stock with $7 price target | 1 | Investing.com | ||
| 28.01. | OKYO Pharma meldet erfolgreiches FDA-Treffen zur klinischen Studie mit Urcosimod | - | Investing.com Deutsch | ||
| 28.01. | OKYO Pharma erhält grünes Licht der FDA für entscheidende NCP-Studie | - | Investing.com Deutsch | ||
| 28.01. | OKYO Pharma receives FDA alignment on Phase 2b/3 trial for NCP treatment | 2 | Investing.com | ||
| 28.01. | OKYO Pharma Announces Successful Type C Meeting with the FDA | 225 | GlobeNewswire (Europe) | FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approachLONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a... ► Artikel lesen | |
| 26.01. | OKYO Pharma erhält FDA-Sondergenehmigung für Urcosimod | 1 | Investing.com Deutsch | ||
| 26.01. | OKYO Pharma stock gets FDA compassionate use approval for urcosimod | 2 | Investing.com | ||
| 23.01. | OKYO Pharma LTD: FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain | 323 | GlobeNewswire (Europe) | LONDON and NEW YORK, Jan. 23, 2026), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases... ► Artikel lesen | |
| 23.01. | OKYO Pharma Ltd - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 06.01. | H.C. Wainwright reiterates Buy rating on OKYO Pharma stock at $7 target | 1 | Investing.com | ||
| 05.01. | OKYO Pharma appoints Robert Dempsey as new CEO | 1 | Investing.com |
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IDEXX LABORATORIES | 520,60 | -4,69 % | Baron Partners Fund is Leveraging IDEXX Laboratories' (IDXX) Long-Term Growth Drivers | ||
| BIOXCEL THERAPEUTICS | 1,350 | -1,46 % | BioXcel Therapeutics kündigt Meilenstein- und Halteprämien für Führungskräfte an | ||
| VOYAGER THERAPEUTICS | 2,900 | -5,84 % | Voyager Therapeutics, Inc. - 8-K, Current Report | ||
| ADAPTIMMUNE THERAPEUTICS | 0,016 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 3,407 | +4,09 % | Anavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update | Company to host a webcast today at 8:30 am Eastern Time NEW YORK, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical... ► Artikel lesen | |
| CELLAVISION | 14,600 | -3,05 % | CellaVision: Solid Quarter driven by Strong Performance in Americas | Organic sales growth:Q4, 2025: 12.2% (-7.4)EBITDA margin:Q4, 2025: 33% (33)Oktober 1st - December 31st, 2025Net sales increased by 5.6% (-7.0) to SEK 197 m (187).Sales increased organically by 12.2%... ► Artikel lesen | |
| PRECISION BIOSCIENCES | 3,300 | -4,07 % | PRECISION BIOSCIENCES INC - 8-K, Current Report | ||
| ZYMEWORKS | 19,300 | 0,00 % | Zymeworks Inc.: Zymeworks Announces Participation in Upcoming Investor Conferences | VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets, while developing a diverse pipeline... ► Artikel lesen | |
| VTV THERAPEUTICS | 27,600 | -4,83 % | vTv Therapeutics Inc.: vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health | HIGH POINT, N.C., Dec. 18, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced a Phase 2 clinical study protocol developed in collaboration... ► Artikel lesen | |
| QUOIN PHARMACEUTICALS | 6,560 | +4,79 % | Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces Submission to Japanese MHLW for Orphan Drug Designation for QRX003 in Netherton Syndrome | Confirmation Received from MHLW That QRX003 Qualifies for Both Orphan Drug Designation and Fast Track Regulatory Review Status Quoin Initiating the Establishment of a Japanese Subsidiary to Facilitate... ► Artikel lesen | |
| NEUPHORIA THERAPEUTICS | 4,060 | +1,25 % | Neuphoria Therapeutics, Inc.: Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions | BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies... ► Artikel lesen | |
| PLIANT THERAPEUTICS | 0,975 | 0,00 % | Pliant Therapeutics, Inc.: Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors | One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment... ► Artikel lesen | |
| MIRA PHARMACEUTICALS | 1,040 | +4,00 % | MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study | Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Association for Cancer Research (AACR)Annual Meeting MIAMI, FLORIDA / ACCESS Newswire / February 3, 2026... ► Artikel lesen | |
| NUVATION BIO | 5,780 | 0,00 % | NSE - Nuvation Bio Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ONCONETIX | 1,060 | 0,00 % | Realbotix announces the sale of subsidiary to Onconetix |
OKYO PHARMA LIMITED gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +12,82 % bei einem Aktienkurs von 2,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OKYO PHARMA LIMITED finden Sie auf Wallstreet Online.